Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery

Author(s): Qiang Fu, Jin Sun, Wenping Zhang, Xiaofan Sui, Zhongtian Yan, Zhonggui He

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 4 , Issue 3 , 2009

Become EABM
Become Reviewer

Abstract:

Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab™) paclitaxel (nab-paclitaxel; Abraxane®) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nabtechnology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect.

Keywords: Nab- technology, anti-cancer drug, paclitaxel, albumin

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 4
ISSUE: 3
Year: 2009
Page: [262 - 272]
Pages: 11
DOI: 10.2174/157489209789206869
Price: $65

Article Metrics

PDF: 76